CCM
HRMY icon

Camber Capital Management’s Harmony Biosciences HRMY Stock Holding History

Camber Capital Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-750,000
Closed -$24.2M – 38
2023
Q4 		$24.2M Buy
+750,000
New +$20.9M 0.62% 29

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $86.2B AUM 12.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Camber Capital Management's HRMY Position: Q1 2024 in Review

Camber Capital Management sold out of Harmony Biosciences (HRMY) in Q1 2024, closing a stake of 750,000 shares — an estimated $24.2M sold.

Camber Capital Management first reported a position in HRMY in Q4 2023 and held it in 1 quarter. The position peaked at $24.2M in Q4 2023. 208 funds tracked by Wall St. Rank hold HRMY as of Q1 2024.

  • Camber Capital Management reported no remaining Harmony Biosciences position as of Q1 2024 after selling out during the quarter.
  • Camber Capital Management sold 750,000 Harmony Biosciences shares in Q1 2024, an estimated $24.2M.
  • Camber Capital Management first reported a position in Harmony Biosciences in Q4 2023 and held it in 1 quarter.
  • Camber Capital Management's Harmony Biosciences position peaked at $24.2M in Q4 2023.
  • 208 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2024.

Based on Camber Capital Management's 13F filing for Q1 2024, filed 15 May 2024.